` NVCR (Novocure Ltd) vs S&P 500 Comparison - Alpha Spread

NVCR
vs
S&P 500

Over the past 12 months, NVCR has significantly outperformed S&P 500, delivering a return of 47% compared to the S&P 500's 8% growth.

Stocks Performance
NVCR vs S&P 500

Loading
NVCR
S&P 500
Add Stock

Performance Gap
NVCR vs S&P 500

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
NVCR vs S&P 500

Loading
NVCR
S&P 500
Add Stock

Competitors Performance
Novocure Ltd vs Peers

Novocure Ltd
Glance View

Market Cap
2B USD
Industry
Health Care

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

NVCR Intrinsic Value
HIDDEN
Show
Back to Top